GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » 1-Year ROIIC %

Zai Lab (HKSE:09688) 1-Year ROIIC % : 3.97% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Zai Lab's 1-Year ROIIC % for the quarter that ended in Sep. 2024 was 3.97%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Zai Lab's 1-Year ROIIC % or its related term are showing as below:

HKSE:09688's 1-Year ROIIC % is ranked better than
58.55% of 1421 companies
in the Biotechnology industry
Industry Median: -11.22 vs HKSE:09688: 3.97

Zai Lab 1-Year ROIIC % Historical Data

The historical data trend for Zai Lab's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab 1-Year ROIIC % Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only -42.61 -1,190.91 -1,405.27 -2,421.62 837.53

Zai Lab Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,426.16 837.53 9.86 36.03 3.97

Competitive Comparison of Zai Lab's 1-Year ROIIC %

For the Biotechnology subindustry, Zai Lab's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Zai Lab's 1-Year ROIIC % falls into.



Zai Lab 1-Year ROIIC % Calculation

Zai Lab's 1-Year ROIIC % for the quarter that ended in Sep. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -2593.632 (Sep. 2024) - -2641.532 (Sep. 2023) )/( 1926.162 (Sep. 2024) - 846.308 (Sep. 2023) )
=47.9/1079.854
=4.44%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Zai Lab  (HKSE:09688) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Zai Lab 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Zai Lab's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab Business Description

Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Ubs Group Ag 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Janus Henderson Group Plc 2102 Investment manager
Du Ying 2101 Beneficial owner
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Fmr Llc 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Invesco Developing Markets Fund 2106 Person having a security interest in shares
Baillie Gifford & Co 2102 Investment manager
Citigroup Inc. 2502 Approved lending agent

Zai Lab Headlines

No Headlines